AtaCor Medical Enrolls First Patients in its ASCEND EV Clinical Study
SAN CLEMENTE, Calif., March 24, 2025 /PRNewswire/ — AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management, announced today that it has initiated its ASCEND EV study. The prospective, non-randomized international study aims to evaluate the safety and performance of AtaCor’s all-in-one Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System in combination with leading commercially available transvenous ICDs. The initial cases were performed at a single clinical site and demonstrated successful sensing and defibrillation of induced ventricular fibrillation using the Atala™ lead in connection to a range of commercially available ICDs.
